Article info

Download PDFPDF

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases
Free

Authors

  • Robert Spiera Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA Department of Medicine, Division of Rheumatology, Weill Cornell Medical College, New York, New York, USA PubMed articlesGoogle scholar articles
  • Sarah Jinich Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA PubMed articlesGoogle scholar articles
  • Deanna Jannat-Khah Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA Department of Medicine, Division of Rheumatology, Weill Cornell Medical College, New York, New York, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Robert Spiera, Department of Medicine, Hospital for Special Surgery, New York, NY 10028, USA; spierar{at}hss.edu
View Full Text

Citation

Spiera R, Jinich S, Jannat-Khah D
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases

Publication history

  • Received April 19, 2021
  • Revised April 30, 2021
  • Accepted May 4, 2021
  • First published May 11, 2021.
Online issue publication 
September 13, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.